Latash Investments LLC Acquires New Holdings in Aquestive Therapeutics, Inc. $AQST

Latash Investments LLC bought a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 243,134 shares of the company’s stock, valued at approximately $1,011,000. Aquestive Therapeutics makes up about 0.7% of Latash Investments LLC’s investment portfolio, making the stock its 7th largest position. Latash Investments LLC owned approximately 0.19% of Aquestive Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Victory Capital Management Inc. grew its holdings in shares of Aquestive Therapeutics by 17.0% in the 3rd quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock valued at $72,000 after buying an additional 1,862 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Aquestive Therapeutics by 6.0% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock worth $156,000 after buying an additional 2,649 shares during the period. Informed Momentum Co LLC raised its stake in Aquestive Therapeutics by 1.8% during the 4th quarter. Informed Momentum Co LLC now owns 155,053 shares of the company’s stock worth $1,002,000 after buying an additional 2,721 shares during the period. Sugar Maple Asset Management LLC lifted its holdings in Aquestive Therapeutics by 5.9% during the first quarter. Sugar Maple Asset Management LLC now owns 58,060 shares of the company’s stock worth $241,000 after acquiring an additional 3,210 shares in the last quarter. Finally, Stifel Financial Corp lifted its holdings in Aquestive Therapeutics by 0.9% during the fourth quarter. Stifel Financial Corp now owns 369,728 shares of the company’s stock worth $2,388,000 after acquiring an additional 3,300 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Up 6.2%

Shares of AQST stock opened at $4.59 on Thursday. Aquestive Therapeutics, Inc. has a 12 month low of $2.93 and a 12 month high of $7.55. The company’s fifty day simple moving average is $4.16 and its 200-day simple moving average is $4.11. The firm has a market cap of $576.09 million, a PE ratio of -7.06 and a beta of 1.49.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The company had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $11.42 million. On average, equities analysts predict that Aquestive Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Julie Krop sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total value of $125,500.00. Following the completion of the sale, the director owned 25,000 shares of the company’s stock, valued at approximately $125,500. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Wall Street Zen cut Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Oppenheimer assumed coverage on Aquestive Therapeutics in a research report on Friday, April 24th. They issued an “outperform” rating and a $8.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $8.50.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.